The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sofant Signs EUR7.3m ESA Contract

4 Nov 2021 07:00

RNS Number : 2806R
NetScientific PLC
04 November 2021
 

NetScientific plc

("NetScientific", the "Group" or the "Company")

 

Sofant Signs €7.3m European Space Agency Contract

 

London, UK - 4 November 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, Sofant Technologies ("Sofant"), the leading 5G and Satcom antenna developer based in Edinburgh, has signed a €7.3M contract with the UK Space Agency ("UKSA") and the European Space Agency ("ESA") to support the commercialisation of its low-cost low-power satellite communications platform, of which 50% can be claimed as non-dilutive grant funding, with the balance coming from Sofant.

 

The funding from the ESA - secured under an ​​Advanced Research in Telecommunications Systems (ARTES) contract - will support Sofant Technologies to complete the commercialisation of a satellite communication terminal, allowing users to connect to the cloud via a new generation of low-latency, super-fast satellite networks.

 

Applying patented and state of the art RF MEMS (radio frequency microelectromechanical systems), Sofant Technologies' platform solves the most pressing power consumption and heat problems faced by the next generation of 5G and satellite communications systems.

 

Eliminating the need for complex and expensive cooling systems, Sofant's patented RF MEMS (radio frequency microelectromechanical systems) platform will enable Satellite Communication (SatCom) and 5G wireless networks to operate with 70% less power.

 

By connecting devices wirelessly via a satellite network, Sofant Technologies' terminal will reduce the needs for terrestrial infrastructure and make it much easier for people in rural and remote locations to get online.

 

With COP26 underway, Sofant's technology is moving towards further environmental savings, with the potential for the technology to be powered by renewable energy. Those relying on solar or wind technology in rural locations will have the ability to connect via their own power sources, further reducing individual carbon footprints in the pursuit of neutral carbon emissions by 2050.

 

This contract follows the recent fundraise in the company, advised by NetScientific's corporate finance and venture capital division EMV Capital Ltd, deploying its capital light investment approach and leveraging non-dilutive funding to raise a total of £843k - including a £300k direct investment from NetScientific.

 

NetScientific has advised on £2.3M of previous investments in Sofant, representing 25.7% of its paid up capital, and is represented on its Board by Dr. Iliev.

 

Commenting on the contract, David Wither, CEO of Sofant Technologies, said: "We are honoured that the UKSA and the ESA have agreed to support the commercialisation of Sofant's technology. They have a clear understanding of the technical challenges faced by the satellite communications industry as it seeks to exploit the promise of a new generation of satellite networks. They also share our belief that a scalable technology platform which solves power consumption and heat problems in phased array antennas is critical for the future wireless communications. We look forward to working with the team at the ESA throughout this project.

 

"This announcement comes as Sofant Technologies gears up for its first Series A funding round, to scale its base in Edinburgh and triple its headcount from 16 to 48 over the contract period. This will create numerous highly-skilled jobs within Scotland's engineering sector, from antenna and product design to component, product and software engineering."

 

Dr. Ilian Iliev, CEO of NetScientific commented: "The UK Space Agency and European Space Agency's support for Sofant further demonstrates the strength of NetScientific's investment thesis - combining our capital light investment approach with access to non-dilutive public funding in high-impact sectors. The non-dilutive funding will support Sofant in going through the next major value inflection points, help attract major industry partners, while limiting dilution to shareholders."

 

 

For more information, please contact:

NetScientific

Via Walbrook PR

Ilian Iliev, CEO 

 

 

 

WH Ireland (NOMAD, Financial Adviser and Broker)

 

Chris Fielding / Darshan Patel 

+44 (0)20 7220 1666

 

 

Walbrook PR

 

Nick Rome/ Paul McManus/

Nicholas Johnson

07748 325 236, 07980 541 893

or 07884 664 686

 

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally. 

 

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities. 

 

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong transatlantic and growing international presence, providing attractive expansion prospects. 

 

NSCI can deploy a capital-light investment structure; utilising the power of the PLC Brand, and the NetScientific balance sheet to anchor future investments and achieve a multiplier effect by attracting 3rd party investment for the portfolio companies. 

 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013 (website: www.netscientific.net).

 

About Sofant Technologies

www.sofant.com

Sofant Technologies is a cutting-edge radio technology company based in Edinburgh, Scotland. The company is applying the unique properties of its patented RF MEMS technology to develop an extremely low power, low-cost platform which solves the most pressing power consumption and heat problems in satellite communications and 5G antenna systems. Sofant's ability to use the fabless semiconductor business model and established volume production methods places the company in a unique position to offer its customers game-changing performance with guaranteed scalability and low cost.

 

Sofant aims to revolutionise satellite communications and to make high band 5G a reality.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABJBLTMTTMBBB
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.